The CL3 containment suite will be used for CCL’s own diagnostic testing, as well as for client projects.
Read More
“Based on PSA alone, my prostate cancer would not have been detected.”
Read More
Prostate cancer is currently a favoured topic by the British media. More awareness that urges men to act and take a test is good, but only if they can get a test, and only if that test can find the condition early.
Read More
CCL is delighted to welcome Professor Andrew Drakeley MD FRCOG as our Fertility Consultant. Andrew will provide advice and guidance to us as we develop our work in reproductive medicine.
Read More
Since we last spoke with Cambridge Clinical Laboratories Chief Scientific Officer, Dr Tony Cooke, we have seen Jonathan Shrewsbury, CCL’s new CEO, join the business. With that, naturally, the focus of the business has evolved. We take five to find out what the focus for the lab is in 2023.
Read More
Come and join the team at Cambridge Clinical Laboratories. We are looking to hire a Laboratory Technician, Hospital Liaison Officer, and Biomedical Scientist. Could it be you?
Read More
Cambridge Clinical Laboratories (CCL) has been announced as the sole global laboratory partner for the FSH receptor (FSH-R) polymorphism test by pMorph.
Read More
The team at Cambridge Clinical Laboratories will be taking a few days rest over Christmas. Read more for details of our closure over the holiday’s and dates for deliveries.
Read More
This Lung Cancer Awareness Month find out more about one of the most common cancers in the UK population and how CCL can support with the diagnosis and treatment pathway.
Read More
Dr Anthony Cooke, who has guided CCL as CEO since 2019, has decided to step back from his CEO role. He will remain part of the private lab’s senior leadership team, staying on as Chief Scientific Officer. Joining the helm is Jonathan Shrewsbury who will take on the role of CEO.
Read More
This Breast Cancer Awareness Month find out more about the most common cancer in the UK population and how CCL can support with the diagnosis and treatment pathway.
Read More
CCL has a range of tests available to support the bowel cancer pathway. Bowel cancer is the UK’s second biggest cancer killer. However, if this disease is diagnosed early it is treatable and curable. An estimated 9 in 10 people will survive bowel cancer if diagnosed at the earliest stage.
Read More
Taking five with Dr Tony Cooke, CCL CEO.
What does the landscape look like for personalised healthcare testing in the UK post Covid? Read on…
Read More
CCL is now running the Oncimmune EarlyCDT Lung test. The EarlyCDT Lung test is a simple finger prick blood test which results can indicate whether an individual has an increased risk of lung cancer.
Read More
This Bowel Cancer Awareness month, Cambridge Clinical Laboratories is announcing that it is opening up the availability of the FIT test (Faecal Immunochemical Test) to all.
Read More
Cambridge Clinical Laboratories reflects on our work this World Health Day 2022.
Read More
Cambridge Clinical Laboratories CEO Dr Anthony Cooke has been announced as Chair of the Scientific Advisory Board for The Laboratory and Testing Industry Organisation.
Read More
Read on for details on when Cambridge Clinical Laboratories will be opening / closed for Christmas 2021.
Read More
Cambridge Clinical Laboratories launches our new suite of tests to support the UK prostate cancer pathway.
Read More
Cambridge Clinical Laboratories (CCL) announces today, Friday 27 August, that CCL will be the UK partner for Prostatype Genomics in bringing the Prostatype® prostate cancer gene test to the UK market.
Read More